Sugi Predict

Sugi Predict / Targets / ASH1L

ASH1L

Histone-lysine N-methyltransferase ASH1L · Q9NR48 · ASH1L on Sugi Atlas →

3,145 patent compounds predicted against ASH1L, 1,707 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL9792860 SCHEMBL9792860 0.56 15/20
SCHEMBL15805914 SCHEMBL15805914 0.47 12/20
SCHEMBL5226675 SCHEMBL5226675 0.45 12/20
SCHEMBL13062940 SCHEMBL13062940 0.52 9/20
SCHEMBL3675588 SCHEMBL3675588 0.74 8/20
SCHEMBL941005 SCHEMBL941005 0.48 8/20
SCHEMBL1091579 SCHEMBL1091579 0.50 7/20
SCHEMBL121883 SCHEMBL121883 0.51 6/20
SCHEMBL3773206 SCHEMBL3773206 0.48 5/20
SCHEMBL3773211 SCHEMBL3773211 0.48 5/20
SCHEMBL3773214 SCHEMBL3773214 0.48 5/20
SCHEMBL7550357 SCHEMBL7550357 0.44 5/20
SCHEMBL64366 SCHEMBL64366 0.37 5/20
SCHEMBL12853965 SCHEMBL12853965 0.37 5/20
SCHEMBL8739866 SCHEMBL8739866 0.35 5/20
SCHEMBL16535474 SCHEMBL16535474 0.35 5/20
SCHEMBL3661287 SCHEMBL3661287 0.74 4/20
SCHEMBL8442468 SCHEMBL8442468 0.64 4/20
SCHEMBL982028 SCHEMBL982028 0.63 4/20
SCHEMBL8440591 SCHEMBL8440591 0.56 4/20

Clinical trials — most relevant to ASH1L by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 PHASE2ACTIVE_NOT_RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas PHASE1/PHASE2UNKNOWN
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors PHASE2RECRUITING
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) PHASE2COMPLETED
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma PHASE1RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia PHASE1RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies nanWITHDRAWN
Mechanisms of Immune Deficiency nanUNKNOWN
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. nanRECRUITING
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
Changes Associated With H. Pylori and Gastric Carcinogenesis nanACTIVE_NOT_RECRUITING
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ASH1L binder may also engage these)

ProteinNameSimilarity
Q99MY8 — 1.000 Q99MY8 →
TET1 Methylcytosine dioxygenase TET1 1.000 landscape →
SETD2 Histone-lysine N-methyltransferase SETD2 0.997 landscape →
Q9UKL3 — 0.997 Q9UKL3 →
A2AEY4 — 0.996 A2AEY4 →
Q90ZS6 — 0.996 Q90ZS6 →
MKI67 Proliferation marker protein Ki-67 0.996 landscape →
Q3V0A6 — 0.996 Q3V0A6 →
Q925H1 — 0.995 Q925H1 →
CDCA2 Cell division cycle-associated protein 2 0.995 landscape →
Q5DTW7 — 0.995 Q5DTW7 →
A6NCI8 — 0.995 A6NCI8 →
E9Q5F9 — 0.995 E9Q5F9 →
Q28DZ0 — 0.995 Q28DZ0 →
Q8BZ32 — 0.994 Q8BZ32 →
Q9WUF3 — 0.994 Q9WUF3 →
O88466 — 0.994 O88466 →
Q9ULD2 — 0.994 Q9ULD2 →
Q3URK3 — 0.994 Q3URK3 →
Q14B71 — 0.994 Q14B71 →
F6ULY3 — 0.994 F6ULY3 →
A0A087WXM9 — 0.993 A0A087WXM9 →
Q86XD8 — 0.993 Q86XD8 →
Q5VWN6 — 0.993 Q5VWN6 →
Q03172 — 0.993 Q03172 →
O60284 — 0.993 O60284 →
Q8IWI9 — 0.993 Q8IWI9 →
NSD1 Histone-lysine N-methyltransferase, H3 lysine-36 specific 0.993 landscape →
Q8C4A5 — 0.993 Q8C4A5 →
Q5R782 — 0.993 Q5R782 →